AVEO: Fotivda combo fails in earlier treatment setting
Boston, USA-based AVEO Oncology, a subsidiary of LG Chem (KRX: 051910), has announced that the TiNivo-2 Phase III trial did not meet its primary efficacy endpoint.
Read full article »
AVEO is a Massachusetts-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer.
Read more